.png){kind=logo}
GC Asia
Adaptimmune secures $225m of new funding
Adaptimmune Therapeutics, the New York-listed UK biopharmaceutical company focused on cancer treatments, has raised $225m to fund further clinical trials for its immunotherapy treatments.
The share sale came after the company’s stock closed 127% higher on Friday, May 29, after it issued a positive clinical update on its exploratory T-cell therapy to the annual meeting of the American Society for Clinical Oncology (ASCO).
The company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) ...Already a subscriber? Login
-
Latest news from Equity
-
Latest news from Equity
